Published: 16 November 2020
Author(s): Claire de Moreuil, Raphael Le Mao, Emmanuelle Le Moigne, Brigitte Pan-Petesch, Cécile Tromeur, Clément Hoffmann, Pierre-Yves Salaun, Michel Nonent, Marc Danguy des Déserts, Xavier Savary, Marie Guegan, Elise Poulhazan, Christophe Leroyer, Karine Lacut, Francis Couturaud
Section: Original article

Venous thromboembolism (VTE) is a frequent and potentially life-threatening disease. Beyond the initial three months of anticoagulation, it is essential to evaluate accurately the recurrence risk of VTE in order to stop or to prolong oral anticoagulation. In patients with VTE provoked by a major transient risk factor, the risk of recurrence is sufficiently low to warrant anticoagulation discontinuation [1–5]. In contrast, when VTE is unprovoked, the risk of recurrence is high and international guidelines recommend indefinite anticoagulation in patients with a low or an intermediate risk of bleeding [2–7].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.